Phenotypes Associated with This Genotype

Genotype
MGI:5428435

• Allelic Composition: Apoe^tm1Unc/Apoe^tm1Unc; Cyp19a1^tm1Esi/Cyp19a1^tm1Esi
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

increased body weight ( J:184647 )

• increased body weight at 3, 6, and 12 months of age

increased liver weight ( J:184647 )

• increase in liver weight at 3 and 6 months of age

cardiovascular system

abnormal aorta bulb morphology ( J:184647 )

• 3 month old mutants exhibit small aortic root lesions that are extensive at 6 months of age

• double mutants tend to have slightly larger lesion sizes than single Apoe mutants

atherosclerotic lesions ( J:184647 )

• mutants develop large atherosclerotic lesions in the aortic root by 12 months of age; lesions are advanced in development and show a clear fibrous component

• however there is little evidence of atherosclerotic plaque formation within the thoracic aorta with only small lesion development seen in the thoracic aorta at 12 months of age

increased systemic arterial blood pressure ( J:184647 )

• mutants have moderately increased mean arterial blood pressure at 3 months of age

hypertension ( J:184647 )

• mutants develop hypertension by 6 months of age which is sustained in older animals

adipose tissue

increased fat cell size ( J:184647 )

• mutants exhibit an increase in adipocyte size with a larger mean diameter compared to wild-type adipocytes, however no difference in the number of individual adipocytes

abnormal gonadal fat pad morphology ( J:184647 )

• increase in gonadal adipose

homeostasis/metabolism

increased circulating glucose level ( J:184647 )

• 3 month old mutants show a small elevation in baseline blood glucose concentration after an overnight fast

decreased circulating insulin level ( J:184647 )

• mutants of all ages show reduced plasma insulin levels

decreased circulating HDL cholesterol level ( J:184647 )

increased circulating cholesterol level ( J:184647 )

• random-fed non-fasting mutants show an increase in serum cholesterol levels

increased circulating LDL cholesterol level ( J:184647 )

increased circulating VLDL cholesterol level ( J:184647 )

increased circulating triglyceride level ( J:184647 )

increased circulating C-reactive protein level ( J:184647 )

• plasma levels of C-reactive protrein (CRP) are increased in 12 month old mutants

increased circulating interleukin-6 level ( J:184647 )

• plasma levels of IL-6 are increased in 12 month old mutants

increased circulating tumor necrosis factor level ( J:184647 )

• plasma levels of TNF-alpha are increased in 12 month old mutants

impaired glucose tolerance ( J:184647 )

• mutants administered a bolus of glucose show elevated plasma glucose

insulin resistance ( J:184647 )

• 3 month old mutants show a blunted plasma glucose response in response to exogenous insulin administration; this blunted response becomes more pronounced with age

immune system

increased circulating C-reactive protein level ( J:184647 )

• plasma levels of C-reactive protrein (CRP) are increased in 12 month old mutants

increased circulating interleukin-6 level ( J:184647 )

• plasma levels of IL-6 are increased in 12 month old mutants

increased circulating tumor necrosis factor level ( J:184647 )

• plasma levels of TNF-alpha are increased in 12 month old mutants

liver/biliary system

abnormal liver morphology ( J:184647 )

• from 6 months of age, livers begin to show yellow coloration

increased liver weight ( J:184647 )

• increase in liver weight at 3 and 6 months of age

increased susceptibility to age-related hepatic steatosis ( J:184647 )

• 3 month old mutants start to show small lipid droplets forming within livers which become more pronounced at 6 and 12 months of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
abdominal obesity-metabolic syndrome		DOID:0060611	OMIM:PS605552	J:184647